Catheter Precision (NYSE: VTAK) agreed to terminate its at-the-market equity offering and completed a strategic institutional financing for up to $36.5 million to accelerate growth. The company converted approximately $9 million of short and long-term liabilities into equity and extended note maturities to two and three years, strengthening liquidity and aligning with long-term investors.
The company said no future equity lines or forward-priced agreements are anticipated; additional transaction details are available in its Form 8-K filings.
Loading...
Loading translation...
Positive
$36.5M institutional financing secured
Approximately $9M liabilities converted into equity
Extended note maturities to 2–3 years
ATM equity program terminated; no future equity lines anticipated
Negative
Conversion into equity may cause shareholder dilution
Press release omits pricing and specific transaction terms
News Market Reaction – VTAK
-33.16%61.5x vol
22 alerts
-33.16%Session close to close
+3.7%Peak Tracked
-52.9%Trough Tracked
$3.17MMarket Cap
61.5xRel. Volume
In the Feb 12 session, VTAK declined 33.16%, reflecting a significant negative market reaction.
Argus tracked a peak move of +3.7% during that session.
Argus tracked a trough of -52.9% from its starting point during tracking.
Our momentum scanner triggered 22 alerts that day, indicating elevated trading interest and price volatility.
Trading volume was exceptionally heavy at 61.5x the daily average, suggesting significant selling pressure.
The stock dropped -33.2% in the session following this news. A negative reaction despite balance she...
Analysis
The stock dropped -33.2% in the session following this news. A negative reaction despite balance sheet strengthening would fit VTAK’s history of mixed responses to positive news. The financing provides access to up to $36.5 million and converts roughly $9 million of liabilities into equity following prior proceeds of $2,177,759.00, but investors may focus on ongoing losses such as the Q3 2025 net loss of $2.251 million. Concerns around prior going‑concern language and potential dilution could weigh on sentiment even as near‑term liquidity improves.
Multi‑year LockeT commitment at a major Irish EP center, eighth EU country.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news has been consistently positive on commercialization and expansion, but price reactions were mixed, with 3 aligned and 2 divergence outcomes.
Recent Company History
Over the last few months, VTAK has focused on commercial expansion of its LockeT and VIVO platforms, including new purchase orders in Germany and Ireland and growth to 15 countries. These updates often highlighted workflow benefits and international adoption, with some days seeing double‑digit gains and others modest declines. Against that backdrop, the new announcement of up to $36.5 million in institutional financing and conversion of about $9 million of liabilities into equity extends the prior balance sheet work disclosed in recent 8‑K filings and follows ongoing efforts to address going‑concern risks noted in the Q3 2025 10‑Q.
Key Terms
at-the-market equity offering program, atm equity offering, form 8-k, schedule 13g, +4 more
8 terms
at-the-market equity offering programfinancial
"agreed to the termination of its at-the-market (“ATM”) equity offering program"
A program that lets a company sell newly issued shares directly into the open market at whatever the current trading price is, usually through a broker, and do so gradually over time instead of all at once. Investors care because it can dilute existing ownership and put steady selling pressure on the stock price, while giving the company a flexible, on-demand way to raise cash — like adding small amounts of water to a pool rather than dumping in a bucket.
atm equity offeringfinancial
"termination of its at-the-market (“ATM”) equity offering program"
An at-the-market (ATM) equity offering is a way for a company to sell newly issued shares directly into the open market over time at prevailing prices instead of in one large sale. Think of it like a baker selling individual slices throughout the day at the store’s current price; it gives the company flexible, on-demand access to cash but can dilute existing shareholders and put downward pressure on the stock if many shares are issued.
form 8-kregulatory
"Please refer to the Company’s Current Report on Form 8-K filed February 6, 2026"
A Form 8-K is a report that companies file with the government to share important news quickly, such as changes in leadership, major business deals, or financial updates. It matters because it helps investors stay informed about significant events that could affect the company's value or stock price.
schedule 13gregulatory
"Catheter Precision, Inc. (VTAK) received a Schedule 13G filing"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
convertible preferred stockfinancial
"multiple new series of convertible preferred stock to raise capital"
Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.
registration rights agreementregulatory
"A registration rights agreement requires Catheter Precision to register resales"
A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.
reverse stock splitfinancial
"A 1‑for‑19 reverse stock split became effective on August 15, 2025"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
going concernfinancial
"Management states there is substantial doubt about the ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
VTAK has Agreed to Terminate its At-The-Market (“ATM”) Equity Offering Program
Company Strengthens Balance Sheet and Aligns Institutional Capital for Long-Term Value Creation
FORT MILL, S.C., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) (“Catheter Precision” or the “Company”), a leader in advanced electrophysiology solutions, today announced that it has agreed to the termination of its at-the-market (“ATM”) equity offering program and has completed a strategic financing transaction with institutional investors for up to $36.5 million to support accelerated growth.
Key Highlights:
ATM equity program to be terminated. No future equity lines of credit or forward-priced agreements are anticipated.
Strategic institutional capital secured to fund expansion
Balance sheet and liquidity significantly strengthened
The company’s short-term notes have been converted to long term by extending maturities out to two and three years
Additional short and long-term liabilities of approximately $9 million on the 9/30/25 balance sheet are being converted into equity
Executive Commentary “This financing and balance sheet restructuring strengthens our financial position and also reinforces institutional investor confidence in our strategy,” said David Jenkins, CEO and Chairman of VTAK.
Jenkins added, “By eliminating legacy financing overhang and aligning ourselves with long-term institutional partners, we’ve enhanced our ability to execute with speed, discipline, and focus.”
Jenkins concluded, “We now move forward from a position of financial strength, supported by capital, stability, and strategic alignment to drive meaningful shareholder value through disciplined growth.”
Capital Strategy Update This strategic institutional investment provides the Company with financial flexibility to:
Advance key growth initiatives
Scale multiple business opportunities
Expand market presence and execution capabilities
Additional Information This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Please refer to the Company’s Current Report on Form 8-K filed February 6, 2026, and February 12th for additional details regarding the transaction.
About Catheter Precision Catheter Precision is a U.S.-based medical device company developing innovative solutions to improve the treatment of cardiac arrhythmias. The Company is committed to bringing new technologies to market through physician collaboration and continued product innovation.
Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to risks and uncertainties described in the Company’s SEC filings, available at www.sec.gov. The Company undertakes no obligation to update these statements except as required by law.
What financing did Catheter Precision (VTAK) announce on February 12, 2026?
Catheter Precision announced a strategic institutional financing of up to $36.5 million. According to the company, the funding supports growth initiatives and strengthens liquidity while aligning with long-term institutional investors.
How did the February 12, 2026 financing affect VTAK's balance sheet?
The financing strengthened VTAK's balance sheet by converting liabilities into equity and extending notes. According to the company, about $9 million of short and long-term liabilities were converted to equity and maturities extended to two and three years.
What change did Catheter Precision make to its ATM program on February 12, 2026?
Catheter Precision terminated its at-the-market (ATM) equity offering program and expects no future equity lines. According to the company, this removes legacy financing overhang and aligns capital with long-term institutional partners.
Will the VTAK financing cause shareholder dilution?
The transaction includes conversion of liabilities into equity, which can dilute existing shareholders. According to the company, approximately $9 million of liabilities were converted to equity, though exact dilution percentages were not disclosed.
Where can investors find more details about the VTAK financing transaction?
Investors should review the company's Form 8-K filings filed February 6 and February 12, 2026 for details. According to the company, those filings contain additional transaction terms and disclosures not included in the press release.
